Matrix-producing metaplastic breast carcinoma – a rare tumor with heterologous elements

Sharma, SK; Siraj, Fouzia

doi:10.3205/000258

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, these 77 articles were excluded. Overall, 65 studies [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ...…”

Section: Resultsmentioning

confidence: 99%

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Metaplastic carcinoma of the breast (MpBC) is a very rare and aggressive type of breast cancer. Data focusing on MpBC are limited. The aim of this study was to describe the clinicopathological features of MpBC and evaluate the prognosis of patients with MpBC. Eligible articles about MpBC were identified by searching CASES SERIES gov and the MEDLINE bibliographic database for the period of 1 January 2010 to 1 June 2021 with the keywords metaplastic breast cancer, mammary gland cancer, neoplasm, tumor, and metaplastic carcinoma. In this study, we also report 46 cases of MpBC stemming from our hospital. Survival rates, clinical behavior, and pathological characteristics were analyzed. Data from 205 patients were included for analysis. The mean age at diagnosis was 55 (14.7) years. The TNM stage at diagnosis was mostly stage II (58.5%) and most tumors were triple negative. The median overall survival was 66 (12–118) months, and the median disease-free survival was 56.8 (11–102) months. Multivariate Cox regression analysis revealed that surgical treatment was associated with decreased risk of death (hazard ratio 0.11, 95% confidence interval 0.02–0.54, p = 0.01) while advanced TNM stage was associated with increased risk of death (hazard ratio 1.5, 95% confidence interval 1.04–2.28, p = 0.03). Our results revealed that surgical treatment and TNM stage were the only independent risk factors related to patients’ overall survival.

show abstract

Section: Resultsmentioning

confidence: 99%

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The neoplasm has high rates of recurrence, at 35%–62%. 12 , 13 P53 mutations are highly visible with frequencies ranging from 53% to 64%. Tumor protein p63, which is a member of the p53 family, is also expressed in these neoplasms and is used as a myoepithelial marker; however, it has no prognostic value.…”

Section: Discussionmentioning

confidence: 99%

A unique presentation of metaplastic breast carcinoma, NOS: A case report

Mremi,

Mwakyembe,

Suleman

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageA rare form of invasive breast carcinoma, NOS, also known as matrix‐producing carcinoma made up of epithelial and mesenchymal components. Usually, they are triple negative and clinically aggressive and respond poorly to neoadjuvant systemic therapy.AbstractMetaplastic breast carcinomas (MBCs) are ductal carcinomas that undergo metaplasia to form nonglandular growth patterns. They are extremely rare, constituting less than 1% of all invasive breast carcinomas. Matrix‐producing carcinoma is an exceedingly rare form of MBC distinguished by a ductal carcinomatous component with direct transition to areas of cartilaginous or osseous differentiation without the presence of an intervening spindle cell element. MBCs are clinically aggressive, but matrix‐producing subtypes have a relatively better prognosis. The tumors are usually triple negative. Therefore, surgery and chemotherapy are the main therapeutic approaches. Our report describes this unique form of MBC with prominent osseous differentiation in a 33‐year‐old female patient. Its distinct histological features and peculiar clinical behavior necessitate a thorough understanding of this one‐of‐a‐kind disease entity.

show abstract

“…Matrix-producing carcinoma of the breast represents a rare subtype of metaplastic breast carcinoma, but hundreds of cases have been documented in the literature [3][4][5][6][7][8][9][10]. The cellular source of matrix-producing carcinoma still lacks clarity, although ultrastructural examination suggests that the tumor cells may arise from both epithelial and myoepithelial cells.…”

Section: Discussionmentioning

confidence: 99%

Large Solitary Lung Metastasis of a Matrix-Producing Metaplastic Breast Carcinoma: A Diagnostic Challenge

Noor,

Lajara,

Bhargava

2023

Cureus

View full text Add to dashboard Cite

Metaplastic breast carcinoma represents a diverse category of invasive breast cancers distinguished by the transformation of neoplastic epithelial cells into squamous cells or cells with mesenchymal appearance. Matrix-producing breast carcinoma is a variant of metaplastic breast carcinoma, an exceedingly uncommon malignancy accounting for less than 1% of all breast tumors. The precise origin of this tumor remains elusive; some molecular research points to a potential derivation from myoepithelial cells, while other studies emphasize the possibility of neoplastic transformation originating from multipotent stem cells. We report a case of recurrent matrix-producing breast carcinoma. The patient presented with a breast mass. The tumor cells displayed a lack of reactivity for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and exhibited a Ki-67 proliferation index of approximately 40%. Additionally, the tumor cells demonstrated significant reactivity for cytokeratins and S100. The patient underwent surgery, radiation, and chemotherapy and then developed metastasis to the lower lobe of her left lung, seven years after primary diagnosis. Diagnosis of metastasis was confirmed by comparing the metastasis to the primary tumor and staining with a panel of immunohistochemical stains. The patient is currently undergoing chemotherapy and immunotherapy.

show abstract

Matrix-producing metaplastic breast carcinoma – a rare tumor with heterologous elements

Cited by 4 publications

References 9 publications

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature

A unique presentation of metaplastic breast carcinoma, NOS: A case report

Large Solitary Lung Metastasis of a Matrix-Producing Metaplastic Breast Carcinoma: A Diagnostic Challenge

Contact Info

Product

Resources

About